Allergan (AGN) Tops Q1 EPS by 39c, Offers FY & Q2 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

Go back to Allergan (AGN) Tops Q1 EPS by 39c, Offers FY & Q2 Guidance

Allergen (AGN) PT Lowered to $180 at Cantor Fitzgerald

April 30, 2018 1:03 PM EDT

Cantor Fitzgerald lowered its price target on Allergen (NYSE: AGN) to $180.00 (from $191.00) while maintaining a Neutral rating following Q1 results.

Analyst Louise Chen commented, "The decrease in our PT is driven by multiple contraction given a lack of earnings visibility in 2019+ (commercial success... More

Allergan (AGN) & Medicines360 Highlight 5-Year Trial Data from Largest On-going IUS Clinical Study

April 30, 2018 8:38 AM EDT

Allergan plc (NYSE: AGN) and Medicines360 presented five-year data from their ongoing multi-center U.S.-based pivotal clinical trial investigating its intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, at the American College of Obstetricians and Gynecologists (ACOG) 2018 annual clinical and scientific meeting in Austin, Texas. The abstract presents five-year pregnancy rates (by Pearl Index and life-table analysis) and safety outcomes from the ongoing study. The Pearl Index in the first year, among women who were 1635 years old when they enrolled in the study, was 0.15 (CI: 0.02, 0.55). The cumulative life-table pregnancy rate at 5 years was 0.92 (CI:... More